ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
Dow Jones
42.840,26
1,18%
Euro vs US Dollar
1,04315
0,00%
Bitcoin
97.262,89
-0,51%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Mainz BioMed NV (MYNZ)

  7. Mainz BioMed NV (MYNZ) News

MYNZ

Mainz BioMed NV (MYNZ)

Mainz BioMed NV
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:MYNZ
DatumZeitQuelleÜberschriftSymbolFirma
19/12/202414h01GlobeNewswire Inc.Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening TestNASDAQ:MYNZMainz BioMed NV
16/12/202423h29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
16/12/202423h00GlobeNewswire Inc.Mainz Biomed Announces Closing of $8.0 Million Follow-On OfferingNASDAQ:MYNZMainz BioMed NV
16/12/202414h00Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MYNZMainz BioMed NV
13/12/202414h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
13/12/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MYNZMainz BioMed NV
13/12/202402h00GlobeNewswire Inc.Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq RulesNASDAQ:MYNZMainz BioMed NV
11/12/202415h22InvestorsHub NewsWireSilexion Is Addressing the MOST COMMON Human Cancer Gene Mutation With RNAi; Recent M&As in the Field Were for Tens of Billions - $SLXNNASDAQ:MYNZMainz BioMed NV
11/12/202414h00Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:MYNZMainz BioMed NV
09/12/202423h11Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:MYNZMainz BioMed NV
09/12/202415h16Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:MYNZMainz BioMed NV
29/11/202414h45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
29/11/202414h45GlobeNewswire Inc.Mainz Biomed Announces Stock SplitNASDAQ:MYNZMainz BioMed NV
15/11/202423h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
12/11/202415h09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
12/11/202415h00GlobeNewswire Inc.Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global MarketsNASDAQ:MYNZMainz BioMed NV
05/11/202414h00Edgar (US Regulatory)Form F-1 - Registration statement for certain foreign private issuersNASDAQ:MYNZMainz BioMed NV
21/10/202414h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
21/10/202414h01GlobeNewswire Inc.Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate UpdateNASDAQ:MYNZMainz BioMed NV
18/10/202422h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
09/10/202423h20Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
08/10/202414h01GlobeNewswire Inc.Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New VersionNASDAQ:MYNZMainz BioMed NV
03/10/202423h11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MYNZMainz BioMed NV
01/10/202414h01GlobeNewswire Inc.Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025NASDAQ:MYNZMainz BioMed NV
18/09/202414h01GlobeNewswire Inc.Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand AmbassadorNASDAQ:MYNZMainz BioMed NV
04/09/202410h01GlobeNewswire Inc.Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlertNASDAQ:MYNZMainz BioMed NV
25/07/202414h01GlobeNewswire Inc.Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User ConvenienceNASDAQ:MYNZMainz BioMed NV
09/07/202415h30AllPennyStocks.comMicro Cap Bid Up Following FDA Submission AnnouncementNASDAQ:MYNZMainz BioMed NV
09/07/202409h01GlobeNewswire Inc.Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening TestNASDAQ:MYNZMainz BioMed NV
02/07/202414h01GlobeNewswire Inc.Mainz Biomed Provides Half Year 2024 Corporate UpdateNASDAQ:MYNZMainz BioMed NV
 Showing the most relevant articles for your search:NASDAQ:MYNZ

Kürzlich von Ihnen besucht

TG
BAS
BASF
TG
D7G
Nel ASA
TG
MBG
MercedesBenz
COIN
SOLUSD
Solana
NASDAQ
TSLA
Tesla
NYSE
MRK
Merck
USOTC
RHHBY
Roche (QX)
NASDAQ
AMZN
Amazon.com
NASDAQ
AAPL
Apple
NASDAQ
GOOGL
Alphabet
USOTC
ADDYY
Adidas (QX)
NASDAQ
MSFT
Microsoft
NASDAQ
NVDA
NVIDIA
NYSE
DIS
Walt Disney
TG
432
Arbor Metals
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten